TABLE 176Mixed-treatment comparison – SIB at 24–28 weeks (mean change from baseline; OC populations): input data

Evidence networkComparisonStudyWMD95% CI
Image app9fu13.jpg
Donepezil vs placeboGauthier et al. (2002)1055.3251.895 to 8.755
Memantine vs placeboReisberg et al. (2003)1425.7002.137 to 9.263
Van Dyck et al. (2007)1430.600−2.591 to 3.791

From: Appendix 9, Mixed-treatment comparisons performed in specified measurement populations

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.